Shire sees level revenues in 2009

Shire has published its financial results for the 2009 fiscal year, during which the company was able to maintain its revenues at an even level.

The pharmaceutical firm posted a total revenue figure of $3.01 billion (1.94 billion pounds) for the full year, which was approximately equal to the amount generated in 2008.

In addition to this the company was able to demonstrate increases in sales and revenues during the fourth quarter, contributing to core product sales for 2009 which were 25 per cent higher than the previous year.

Angus Russell, chief executive officer of Shire, described the results as an excellent performance in what was a “challenging and transformational” year for the company.

He added: “We look forward to growing revenues and earnings in 2010 and reiterate our aspirational target of mid-teen revenue growth on average between 2009 and 2015.”

Last week, Shire reported positive data from a phase III trial of velaglucerase alfa, its investigational treatment for type one Gaucher disease.